Navigation Links
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Date:12/10/2012

rugs.  Aequus is a majority owned subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC).

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Aequus' modular GlycoPolymer technology (including, without limitation, the drug candidate AQB-101) include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with glycoengineered protein-based biotherapies (including, without limitation, AQB-101), in particular including, without limitation, that Aequus application of modular GlycoPolymer technology to biologically active proteins and peptides may not facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience; that AQB-101 may not demonstrate the utility of the GlycoPolymer technology platform; determinations by regulatory, patent and administrative governmental authorities; CTI's and Aequus ability to continue to raise capital as needed to fund their operations; competitive factors; technological developments; costs of developing, producing and selling Aequus product candidates; and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, Aequus and CTI do not intend to update or alter such forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:

Ronald Berenson, M.D.
206-790-1094
rberenson@aequusbio.com


'/>"/>
SOURCE Aequus BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
3. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
10. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... July 23, 2014  RT Oncology Services Corporation today ... join its board of directors. Mr. Mundie is currently ... he works on strategic projects within the company and ... chief research and strategy officer. ... RainTree, said, "Craig is a visionary technology executive. His ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies ... market entry results in $5.4 billion in lost savings ... by economic consulting firm Matrix Global Advisors ... Required by the Food and Drug Administration ... are intended to improve drug safety by ensuring that ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
(Date:7/23/2014)... Greenville, SC (PRWEB) July 23, 2014 AidJoy ... celebration of philanthropy at Zen on September 5, ... business community and AidJoy supporters are expected to attend this ... of our triumphs of the past six years," says Jess ... time to pause to reflect on this moment in AidJoy’s ...
(Date:7/23/2014)... "I wanted a better way to keep track of all ... pressure and pulse rate," said an inventor from Long Beach, ... a bunch of different devices, so I invented one that ... to make it easier to monitor health conditions. The invention ... enables the user to have more control over his or ...
(Date:7/23/2014)... athletes who suffered repeated blows to the head during ... Those clumps suggest the athletes had a disease called ... tests that might be able to detect CTE in ... Chemical & Engineering News (C&EN) , the weekly news ... article, Lauren Wolf, a senior editor at C&EN, explains ...
(Date:7/23/2014)... The Centers for Disease Control and Prevention applauded ... 2010 to 2012. Formerly known as “the nation’s medicine ... to some of the strongest opiates, such as Oxycontin, which ... launched an initiative to crack down on these rampant pill ... that existed in the state just a few years ago. ...
(Date:7/23/2014)... Fla. (PRWEB) July 23, 2014 ... results from leading academic institutions uncovering the importance ... opinions surrounding the need for breast self-exams is ... there is proof today for keeping this healthy ... cases mislead about the significance of breast self-exams ...
Breaking Medicine News(10 mins):Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:Historical and Current Research Points to Importance of Breast Self-Exams 2
... for New York Blood Center (NYBC), NEW YORK, ... a blood drive on Monday, June 2 at 1011 ... School Gymnasium. Hours are from,9:30am-3:00pm, The Archdiocese of ... York,Blood Center; His Eminence Edward Cardinal Egan serves as ...
... WASHINGTON, May 30 The Department of,Veterans Affairs (VA) ... identified as being ill or injured from Operation,Enduring Freedom ... over 500,000 OEF-OIF veterans who have been,discharged from active ... "We promised to reach out to every OEF ...
... whole milk is just as effective, costs less and is ... is also commonly used as an oral contrast agent in conjunction ... , The study included 215 patients undergoing abdominal and pelvic CT, ... patients were given an IV contrast media; 115 were also given ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... May 30 Insulet Corporation,(Nasdaq: PODD ), ... its,OmniPod(R) Insulin Management System, today announced the company ... Obesity Conference.,Management is scheduled to present an overview ... June 6, 2008 at The Hotel Nikko in ...
... New Video ,Milestones in Oncology, Presentations at ... Society for Translational Oncology,(STO) is pleased to announce ... valuable video presentations for practicing,oncologists., (Logo: ... on the occasion of the 2008 Annual Meeting ...
Cached Medicine News:Health News:New York's Catholic Archdiocese Hosting June 2 Blood Drive 2Health News:VA Begins Next Phase of Combat Vet Outreach 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Society for Translational Oncology Launches Updated Website 2
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: